Literature DB >> 25445944

Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?

Luke S Howard1, Pisana Ferrari2, Sanjay Mehta3.   

Abstract

In recent years, many new, effective therapies for pulmonary arterial hypertension (PAH) have become available and are widely used, yet the long-term prognosis for patients with PAH remains poor. In the absence of a cure, physicians' expectations of PAH-specific therapies are to: 1) improve patients' symptoms and functional capacity; 2) slow disease progression; and 3) improve survival. However, patients with PAH may prioritise other more tangible needs, such as improvements in their ability to carry out their daily tasks and increase their quality of life. Patients with PAH have also called out for social and emotional support from their physicians, caregivers, families and patient associations. Therefore, it is necessary that clinical trials of PAH-specific treatments include end-points that are meaningful to both patients and physicians, and that a multidisciplinary approach to the management of patients with PAH takes into consideration the broader aspects of patients' and caregivers' needs and wishes beyond simple physiological measurements. ©ERS 2014.

Entities:  

Mesh:

Year:  2014        PMID: 25445944     DOI: 10.1183/09059180.00007514

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  5 in total

1.  Healthcare pathway and patients' expectations in pulmonary fibrosis.

Authors:  Vincent Cottin; Arnaud Bourdin; Bruno Crestani; Grégoire Prévot; Marie Guérin; Benoit Bouquillon
Journal:  ERJ Open Res       Date:  2017-04-12

Review 2.  Anxiety and depression in patients with pulmonary hypertension: impact and management challenges.

Authors:  Maurizio Bussotti; Marinella Sommaruga
Journal:  Vasc Health Risk Manag       Date:  2018-11-08

3.  The importance of patient perspectives in pulmonary hypertension.

Authors:  Michael D McGoon; Pisana Ferrari; Iain Armstrong; Migdalia Denis; Luke S Howard; Gabi Lowe; Sanjay Mehta; Noriko Murakami; Brad A Wong
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

4.  Improving communication between healthcare providers and pulmonary arterial hypertension patients: a survey of patient preferences.

Authors:  Jacqueline Brewer; Mary Bartlett; David Harris; Christine Hui
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

Review 5.  Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Authors:  Adam M Henrie; James J Nawarskas; Joe R Anderson
Journal:  Core Evid       Date:  2015-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.